The cell surface and extracellular matrix polysaccharide, heparan sulfate (HS) 23 conveys chemical information to control or influence crucial biological processes. 24
Introduction 40
Protein glycosylation, the post-translational modification of proteins in 41 which carbohydrate moieties are conveniently attached, is seen as the new 42 frontier in the field of glycomics (Martin et al., 2009) . Glycosylation is the most 43 abundant post-translational modification and plays a vital role in protein function 44 (Haltiwanger and Lowe, 2004) . Heparan sulfate (HS) is a sulfated 45 glycosaminoglycan (GAG) found on the cell membrane and in the extracellular 46 matrix throughout the animal kingdom (Cássaro and Dietrich, 1977; Medeiros et 47 al., 2000) . Alongside heparin (Hep), HS is a member of the GAG family which are 48 present in tissues as proteoglycans, where the polysaccharide chains are 49 covalently bound to a protein backbone. Their chains are mainly composed of 50 repeating disaccharide units of 1,4 linked uronate, either β-D-glucuronate or α-51 L-iduronate, and α-D-glucosamine, where N-acetyl-D-glucosamine residues 52 become de-N-acetylated and N-sulfated, then, β-D-glucuronates undergo 53 epimerization at C5 to α-L-iduronates (IdoA). Furthermore, sulfate groups may be 54 added at C2 of uronate residues, C6 of the glucosamine residues, and less 55 commonly, at C3 of glucosamine residues (Dietrich et al., 1983; Meneghetti et 56 al., 2015) . Such fine-tuning is the result of a series of enzymatic reactions that do 57 not modify the HS chains completely, giving rise to complex substitution patterns. 58 A central hypothesis in the field is that the HS chain substitution pattern 59 encodes its capability to influence many key biological processes (Cavalheiro et It is now appreciated that there exists complex and regulated 67 biosynthetic machinery capable of producing finely-tuned HS structures and that 68 the heterogeneity characteristic of this system will affect networks of proteins, 69 and eventually, become evident in biological terms. 70
Template driven biosynthesis is employed for nucleic acids and proteins, 71 but the biosynthesis of HS exhibits no analogous system. The order in which the 72 enzymatic reactions are carried out by GAG modifying enzymes positioned 73 throughout the ER and Golgi apparatus is a source of continuing debate despite 74 several attempts to determine biosynthetic routes. A feasible order for the 75 enzyme activity has been proposed and a biosynthetic outline able to explain the 76 relative abundance of both common and uncommon structures and that is 77 consistent with experimental observations has also been advanced (Meneghetti 78 et al., 2017; Rudd and Yates, 2012) . Meanwhile, the cell-defined localization of 79 HS modifying enzymes has been questioned, since they have been shown to be 80 located at the cell surface (Delos et al., 2018) . It has also been shown that the 81 localization of EXT1/EXT2 in distinct Golgi cisternae modulates the synthesis of 82 HS (Chang et al., 2013) , suggesting that vesicular trafficking could play an 83 important role in the regulation of HS biosynthesis. Hence, the interrogation of 84 cargo sorting, vesicle assembly and trafficking that takes place to deliver GAG 85 biosynthetic enzymes throughout the ER and Golgi, is necessary for the complete 86 description of HS biosynthesis and, hence, the success of subsequent structure 87 and function studies. 88 Vesicular trafficking is mediated by protein-coated vesicles called 89 coatomer protein complex I (COPI) and II (COPII). The COPI coat comprises a 90 complex of seven subunits α-, β-, β'-, δ-, ε-, γ-and ζ-COP, which are 91 biochemically grouped into cage-like (B-) and an adaptor-like (F-) subcomplexes 92 (Arakel and Schwappach, 2018 of Golgi-resident glycosyltransferases through the ER-Golgi pathway mediated 102 by coated vesicles (Gill et al., 2010; Liu et al., 2018; Storrie et al., 1998; Todorow 103 et al., 2000) . The different localization of these enzymes in the secretory pathway 104 allows newly synthesized glycoconjugates to encounter glycosyltransferases in a 105 non-uniform distribution to perform glycosylation (Emr et al., 2009; Puthenveedu 106 and Linstedt, 2005) . Mechanisms involved in glycosyltransferase retention in 107 different compartments and within distinct Golgi cisternae may ensure the 108 production of a wide structural variety of compounds, a key characteristic of these 109 molecules, and may reflect the complexity of glycoconjugate synthesis. 110
It has also become clear that the search for the precise control of HS 111 biosynthesis through the modulation of individual enzymes is ineffective, while 112 the Golgi dynamics remain poorly understood and the different cellular contexts 113 encountered have been largely ignored. Artificial Golgi systems have been built 114 as test beds to better understand how the natural Golgi controls the biosynthesis 115 of GAGs and ultimately, for the design of bioengineered heparin (Martin et al., 116 2009) but, again, the natural Golgi dynamics and cellular context has not been 117 taken into account. Thus, it seems probable that further regulatory mechanisms 118 are at work; ones that are, perhaps, not apparent at the level of individual 119 biosynthetic enzymes. It was with this in mind that the authors have embarked on 120 the present investigation. 121
In the present study, the influence of vesicular trafficking mediated by 122 COPI and COPII in the distribution, along the early secretory pathway, of HS-123 modifying enzymes in the regulation of HS biosynthesis was evaluated. 124 Furthermore, the effect of pharmacological agents that inhibit vesicular trafficking 125 and overstimulate HS synthesis, which leads to changes in HS-modifying enzyme 126 dynamics and result in altered HS structure, were explored. This study represents 127 a first step towards gaining an understanding of how the natural Golgi controls 128 the biosynthesis of HS and to determining whether cells can be bioengineered to 129 produce tailored GAG structures. 130 131
Results

132
Subcellular localization of fluorescently tagged HS3ST5 133
Initially, the distribution profile of HS-modifying enzymes in coated vesicles 134 was analyzed in endothelial cells (EC) by confocal microscopy (Fig. S1 ). 135
Regardless of the position in the hierarchical sequence of the biosynthetic 136 process, the enzymes involved in HS biosynthesis (NDST1, C5-epimerase, 137 HS3ST1 and HS3ST3A) showed similar localization in COPI and COPII vesicles. 138 3-O-sulfotransferase, the last enzyme to modify the HS chains according to the 139 classic HS biosynthetic pathway, was chosen as a tracker and had its subcellular 140 localization investigated using overexpression systems in EC cells. The 141 overexpression of this HS-modifying enzyme was confirmed by RT-PCR using 142 cloning primers (HS3ST5-BglII and HS3ST5-BamHI), in concert with confocal 143 microscopy and flow cytometry. Only transfected cells showed a band at the 144 expected size for tagged-HS3ST5 ( Fig. S2 A) . In addition, EC-HS3ST5 cells also 145 showed increased total and tagged HS3ST5 protein expression levels, which 146 were analyzed by anti-HS3ST5 antibody (Fig. S2 B) and direct fluorescence of 147 GFP assays ( Fig. S2 C) , respectively. 148
The localization of the overexpressed protein in the Golgi apparatus and 149 coated vesicles was confirmed by immunostaining of the cells using specific 150 antibodies labelled with Alexa Fluor ® 633. As shown in Fig. 1 A, HS3ST5 151 colocalized both with GM130, cis-Golgi protein marker, and Golgin97, a trans-152
Golgi protein marker, confirming HS3ST5 localization in both cisternae of the 153
Golgi apparatus and highlighting that the enzyme is trafficked continually 154 amongst the different Golgi cisternae. HS3ST5 exhibited a similar distribution in 155 COPI, exemplified by α-COP and β-COP subunits, and COPII, represented by 156 staining of the Sec23 subunit, further confirming that HS3ST5 is cycled constantly 157 in the ER-Golgi pathway ( Fig. 1 B) . Further analysis has been conducted using 158 super resolution microscopy. The results clearly showed the colocalization and 159 putative interface of HS3ST5 with different coated vesicle subunits ( Fig. 1 C) . 160 161
Effects of brefeldin A on the localization of HS-modifying enzymes in 162 vesicular trafficking 163
In order to evaluate the influence of vesicular trafficking on the transport of 164 HS-modifying enzymes along the secretory pathway, EC-HS3ST5 cells were 165 treated with brefeldin A (BFA), a pharmacological inhibitor of ADP-ribosylation 166 factors, which are responsible for recruitment of COPI subunits (Peyroche et al., 167 1999 ). In the presence of BFA, HS3ST5 displayed higher levels of colocalization 168 in COPII vesicles, indicating that the enzyme was maintained during anterograde 169 transport ( Fig. 2 A) . It is known that BFA causes Golgi cisternae disassembly and 170 the redistribution of proteins from the cis and medial-Golgi into the ER (Kolset et 171 al., 2002; Lippincott-Schwartz et al., 1989) . As expected, the BFA treatment 172 induced disassembly of the Golgi indicated by GM130 and Golgin97 scattered staining ( Fig. 2 B) . The effect of BFA was also followed by changes in HS3ST5 174 distribution along the Golgi cisternae from cis-to trans-Golgi ( Fig. 2 B) . 175
The profile of other HS-modifying enzymes (NDST1, C5-epimerase, 176
HS2ST, HS3ST1 and HS3ST3A) in the presence of BFA, relative to HS3ST5, 177 was also analyzed by immunostaining and confocal microscopy. All enzymes 178 presented colocalization with HS3ST5 ( Fig. 3) , showing that the HS-modifying 179 enzymes are localized in the same Golgi cisternae. 180 181
Vesicular trafficking and Golgi apparatus localization of HS3ST5 changes 182 with heparin treatment 183
Endothelial cells in the presence of heparin upregulate the synthesis of HS 184 with increasing amounts of trisulfated disaccharide (Nader et al., 1989) . In order 185 to assess whether this was the result of changes in the localization of HS-186 modifying enzymes along the Golgi cisternae, the cells were exposed to heparin 187 and the distribution profile of the HS3ST5 relative to coated vesicles and Golgi 188 apparatus was analyzed by confocal microscopy after immunofluorescence 189 staining. There were no changes in HS3ST5 distribution in either COPI and COPII 190 vesicles ( Fig. 4 ). However, changes in HS3ST5 distribution within the Golgi were 191 observed ( Fig. 5 ). While the HS3ST5 was preferentially present in the cis-Golgi 192 in cells with no treatment, or during the first hour of heparin exposure, HS3ST5 193 changed its distribution from cis to trans-Golgi in subsequent hours (2-3 h). 194 195 Vesicular trafficking of HS3ST5 influences the structure of HS 196 In order to confirm the functional relationships between the structure of HS 197 and vesicular trafficking under heparin stimulation, we performed metabolic 35 S-198 sulfate labeling of HS followed by analysis of the resulting HS structure by 199 enzymatic digestion. The disaccharide composition revealed an increase in the 200 trisulfated disaccharide proportion for the HS present in the cell extract and 201 secreted to the media ( Fig. 6 and Table S1 ). As expected, changes were first 202 detected in the cell extract ( Fig. 6 A) followed by changes in the HS secreted to 203 the media (Fig. 6 B) . Importantly, these results correlate with the changes in 204 HS3ST5 trafficking from cis-to trans-Golgi and recycling to cis again ( The increase in HS sulfation could also be the result of sulfotransferase 211 along with PAPS synthase upregulation. To further confirm our hypothesis that 212 the vesicle trafficking instead is responsible for the detected structural changes, 213 protein and gene expression experiments were conducted. Flow cytometry 214 analysis for specific HS-modifying enzymes (NDST1, C5-Epimerase, HS2ST and 215 HS3ST5) indicated that the protein levels remained unchanged throughout the 216 heparin treatment ( Fig. 7 A) . Gene expression analysis also showed significant 217 decrease in both PAPS synthase isoforms during heparin treatment ( Fig. 7 B) . 218
Together, these results further support the hypothesis that vesicular trafficking, 219 rather than protein/gene expression, regulates HS biosynthesis. later. Whereas the γ-COP1 subunit showed a reduction in its mRNA level in 4 h, 235 γ2-COP and ζ1-COP presented significant increases in their gene expression 236 during this time period; ζ-COP1 being the principal COPI subunit experiencing 237 the highest modification in gene expression. As for Sec24, gene expression of 238 only isoforms A and B changed, and reduction in mRNA levels alone during the 239 early phase of heparin stimulus was observed ( Fig. 8 B) . 240
In summary, the results show that upon heparin treatment, cargo sorting 241 associated proteins have their gene expression altered first, followed by changes 242 in genes that code for coat proteins linked to vesicle trafficking within the Golgi 243 cisternae. Collectively, these results are in agreement with the spatial and shown, however, that the vesicular trafficking influences both spatial and 257 temporal localization of many glycosyltransferases along the ER-Golgi pathway, 258 regulating the sequential order in which these enzymes act upon glycoconjugate 259 synthesis (Tu and Banfield, 2010) . 260
In the current work, we investigated the influence of COPI and COPII 261 coated vesicles on the trafficking of HS-modifying enzymes in early secretory 262 pathways using endothelial cells previously transfected with tagged HS3ST5. We 263 observed that the tagged enzyme displayed similar distribution in coated vesicles, 264 as well as in both cis-and trans-Golgi. However, the HS3ST5 distribution profile 265 changed upon pharmacological treatment. 266
In the presence of BFA, HS3ST5 localized preferentially in COPII vesicles 267 and at the trans-Golgi. Furthermore, regardless of the position in the hierarchical 268 sequence of the biosynthetic process, other enzymes involved in HS biosynthesis 269 (NDST1, C5-Epimerase, HS2ST, HS3ST1 and HS3ST3A) displayed similar 270 localization, suggesting that these enzymes are also present in the trans-Golgi. and streptomycin (100 µg/mL) (Gibco, CA, USA) at 37 °C in a humidified 330 atmosphere of 2.5% CO2. At 80-85% confluence, the cells were detached with a 331 solution of pancreatin (2.5%) diluted 1:10 (v/v) in EBSS, collected by 332 centrifugation, suspended in F12 medium as described above (Buonassisi and 333 Venter, 1976) . 
Super-Resolution Ground State Depletion (SR-GSD) Microscopy 366
Transfected cells were seeded on 18 mm high precision round coverslips 367 (Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany) placed in 12-368 well plate (2 x 10 4 cells/coverslip). After 3 days, the cells were thrice washed with 369 iced PBS and fixed in two steps. Initially, cells were treated with buffer A (5 mM 370 EGTA, 5 mM MgCl2, 5 mM glucose, 10 mM MES, 150 mM NaCl) containing 0.3% 371 glutaraldehyde and 0.01% saponin for 2 min at room temperature and, then, with 372 0.5% glutaraldehyde diluted in buffer A for 10 min at room temperature. After 373 washing, the cells were treated with 0.1% NaBH4 in PBS for 7 min at room 374 temperature, washed and incubated with blocking solution (0.1% saponin, 5% 375 The Δ-degradation products of HS were generated for three independent 422 experiments and the products of digestion combined prior to analysis to allow 423 detection. Therefore, the results represent an overall trend and were expressed 424 as monosulfated, disulfated and trisulfated disaccharide groups. 425
426
RNA extraction and real-time PCR 427
Total RNA was extracted from cultured cells using Trizol reagent 428 (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. RNA 429 extraction was performed for wild type and transfected cells as well as to 430 transfected cells subjected to heparin treatment (20 µg/mL). Reverse 431 transcriptase reaction was performed from 2 µg of total RNA by using ImProm-432 II TM Reverse Transcription System (Promega). Aliquots of cDNA obtained were 433 amplified in PCR and quantitative real-time PCR reactions, using the primers 434 described in Table S3 . PCR reactions were performed using Master Mix (2X) 435 (Promega) and carried out at an initial denaturation step of 95 °C for 2 min, 436 followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 55 °C for 30 437 s and extension at 72 °C for 2 min, and final extension step at 72 °C for 5 min. 438
The PCR products were analyzed on 1% agarose gels in TAE buffer at 100 V for 439 30 min. In addition, real-time PCR amplifications were performed using Maxima® 440 SYBER Green Master Mix 2X (Fermentas, Waltham, MA, USA). The reactions 441 were first subjected to an initial denaturation step at 95 °C for 10 min, followed by 442 40 cycles at 95 °C of 15 s (denaturation step) and at 60 °C for 1 min (annealing 443 /extension steps). Melting curves were generated after the last amplification cycle 444 to assess the specificity of the amplified products. Epimerase, H3ST1 and HS3ST3A) in COPI and COPII vesicles. Fig. S2 shows 460 fluorescently tagged HS3ST5 expression in transfected endothelial cells. Table  461 S1 shows the relative amounts of monosulfated, disulfated and trisulfated 462 disaccharides of HS extracted from transfected cells treated with heparin. Table  463 S2 describes the set of antibodies used in immunofluorescence and flow 464 cytometry assays. Table S3 shows 
